Once-weekly antiretrovirals on the horizon
HIV diagnoses continue to fall in US states with high PrEP coverage, while others are left behind
Broadly neutralising antibodies may be partners for long-acting antiretrovirals
Islatravir plus lenacapavir could be the first once-weekly oral HIV treatment
Six-country African PrEP study achieves high levels of persistence and good adherence in young women
People-centred blood pressure management improves blood pressure in people with HIV
Prostate cancer diagnosed later in US men with HIV
Some children who start antiretrovirals very early may control HIV after stopping treatment
Far fewer HIV infections in Australian PrEP users – consistent use is key
Huge increase in PrEP uptake when services offer choice, flexibility and injectable PrEP, African study shows
Switch to an integrase inhibitor leads to greater weight during and after the menopause
Menopausal status should be considered before switching to an integrase inhibitor